Replimune melanoma drug wins support of FDA panel
Replimune melanoma drug wins support of FDA panel
Replimune
Services: Oncolytic immunotherapies, RP1 for anti-PD1 failed melanoma, cancer immunotherapy
Company Info
Upcoming Milestones & Key Dates
Q3/Q4 2026
Earnings
Q2 2026 earnings call
Recent News
Replimune to ride wave of physician support to launch advanced melanoma therapy
Replimune to ride wave of physician support to launch advanced melanoma therapy
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer's data
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer's data
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more. Reported by BioSpace on 2026-07-29.
FDA reminds investors that re-evaluations don’t equal new conclusions. Just ask Capricor and Replimune
FDA reminds investors that re-evaluations don’t equal new conclusions. Just ask Capricor and Replimune
FDA reminds investors that re-evaluations don’t equal new conclusions. Just ask Capricor and Replimune
FDA reminds investors that re-evaluations don’t equal new conclusions. Just ask Capricor and Replimune. Reported by Endpoints News on 2026-07-28.
FDA staff say Replimune's pivotal melanoma trial failed to prove RP1 works, pushing down stock
FDA staff say Replimune's pivotal melanoma trial failed to prove RP1 works, pushing down stock
FDA staff say Replimune's pivotal melanoma trial failed to prove RP1 works, pushing down stock
FDA staff say Replimune's pivotal melanoma trial failed to prove RP1 works, pushing down stock. Reported by Endpoints News on 2026-07-28.
Leadership Team
Careers & Job Openings